Results 81 to 90 of about 138,715 (220)
Age-related macular degeneration (AMD) is a prevalent and incurable condition affecting the central retina and posing a significant risk to vision, particularly in individuals over the age of 60.
Saranya Velmurugan+4 more
doaj +1 more source
Complement inhibitors for age-related macular degeneration [PDF]
Given the relatively high prevalence of age-related macular degeneration (AMD) and the increased incidence of AMD as populations age, the results of trials of novel treatments are awaited with much anticipation.
Chakravarthy, Usha+2 more
core +1 more source
Macrophages related to Bruch's membrane in age-related macular degeneration [PDF]
Murray C. Killingsworth+2 more
openalex +1 more source
Nutrigenomics of Age-Related Macular Degeneration [PDF]
Lutein (L) and zeaxanthin (Z) are nutrients that reduce the risk of age-related macular degeneration (AMD). As micronutrients that selectively accumulate in the retina of the eye, L/Z can protect the macula from oxidative damage that contributes to AMD ...
Lin, Durpri
core +1 more source
A Population-Based Ultra-Widefield Digital Image Grading Study for Age-Related Macular Degeneration-Like Lesions at the Peripheral Retina. [PDF]
Our understanding of the relevance of peripheral retinal abnormalities to disease in general and in age-related macular degeneration (AMD) in particular is limited by the lack of detailed peripheral imaging studies.
Bird, AC+6 more
core +1 more source
Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. [PDF]
Theo L. van der Schaft+3 more
openalex +1 more source
Prevalence of age related macular degeneration in persons aged 50 years and over resident in Australia. [PDF]
R. A. Mitchell
openalex +1 more source
QM107, a novel CD148 (RTP Type J) activating peptide therapy for treating neovascular age-related macular degeneration. [PDF]
BACKGROUND AND PURPOSE: Angiogenesis is a pathological component of neovascular age-related macular degeneration. Current therapies, although successful, are prone to high levels of patient non-response and a loss of efficacy over time, indicating the ...
Arokiasamy, S+11 more
core +1 more source